AU2013258566B2 - Pyrazole derivative and use thereof for medical purposes - Google Patents

Pyrazole derivative and use thereof for medical purposes Download PDF

Info

Publication number
AU2013258566B2
AU2013258566B2 AU2013258566A AU2013258566A AU2013258566B2 AU 2013258566 B2 AU2013258566 B2 AU 2013258566B2 AU 2013258566 A AU2013258566 A AU 2013258566A AU 2013258566 A AU2013258566 A AU 2013258566A AU 2013258566 B2 AU2013258566 B2 AU 2013258566B2
Authority
AU
Australia
Prior art keywords
constipation
administration
compound
week
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2013258566A
Other languages
English (en)
Other versions
AU2013258566A1 (en
Inventor
Yukihiko Hotei
Masayuki Isaji
Hidetoshi Isawa
Itaru MIYASHITA
Masaaki TAKEMURA
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kissei Pharmaceutical Co Ltd
Original Assignee
Kissei Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kissei Pharmaceutical Co Ltd filed Critical Kissei Pharmaceutical Co Ltd
Publication of AU2013258566A1 publication Critical patent/AU2013258566A1/en
Application granted granted Critical
Publication of AU2013258566B2 publication Critical patent/AU2013258566B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
    • C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2013258566A 2012-05-07 2013-05-02 Pyrazole derivative and use thereof for medical purposes Active AU2013258566B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012105847 2012-05-07
JP2012-105847 2012-05-07
PCT/JP2013/062755 WO2013168671A1 (ja) 2012-05-07 2013-05-02 ピラゾール誘導体及びその医薬用途

Publications (2)

Publication Number Publication Date
AU2013258566A1 AU2013258566A1 (en) 2014-11-27
AU2013258566B2 true AU2013258566B2 (en) 2017-03-16

Family

ID=49550709

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013258566A Active AU2013258566B2 (en) 2012-05-07 2013-05-02 Pyrazole derivative and use thereof for medical purposes

Country Status (15)

Country Link
US (2) US9273085B2 (enExample)
EP (1) EP2848254B1 (enExample)
JP (2) JP5663699B2 (enExample)
KR (1) KR101868991B1 (enExample)
CN (1) CN104284665B (enExample)
AU (1) AU2013258566B2 (enExample)
BR (1) BR112014027841B1 (enExample)
CA (1) CA2872002C (enExample)
DK (1) DK2848254T3 (enExample)
ES (1) ES2601127T3 (enExample)
MX (1) MX359988B (enExample)
PL (1) PL2848254T3 (enExample)
PT (1) PT2848254T (enExample)
RU (1) RU2602739C2 (enExample)
WO (1) WO2013168671A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX366925B (es) 2010-11-04 2019-07-31 Albireo Ab Inhibidores de ibat para el tratamiento de enfermedades hepaticas.
US9273085B2 (en) * 2012-05-07 2016-03-01 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative and use thereof for medical purposes
CN104955481B (zh) 2013-02-04 2017-10-24 大正制药株式会社 便秘症的预防或治疗药
CA2952406A1 (en) 2014-06-25 2015-12-30 Ea Pharma Co., Ltd. Solid formulation and method for preventing or reducing coloration thereof
CN106573033A (zh) * 2014-06-25 2017-04-19 Ea制药株式会社 固体制剂及其稳定化方法
CN112469407B (zh) 2018-03-28 2024-10-01 阿沃林特有限公司 用于治疗餐后低血糖症的方法
JP7391048B2 (ja) 2018-06-05 2023-12-04 アルビレオ・アクチボラグ ベンゾチア(ジ)アゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
KR20210024033A (ko) 2018-06-20 2021-03-04 알비레오 에이비 오데빅시바트의 약학 제제
US11801226B2 (en) 2018-06-20 2023-10-31 Albireo Ab Pharmaceutical formulation of odevixibat
US11549878B2 (en) 2018-08-09 2023-01-10 Albireo Ab In vitro method for determining the adsorbing capacity of an insoluble adsorbant
US11007142B2 (en) 2018-08-09 2021-05-18 Albireo Ab Oral cholestyramine formulation and use thereof
CN113453753B (zh) 2019-02-06 2024-07-23 阿尔比里奥公司 苯并硫氮杂环庚三烯化合物及其用作胆汁酸调节剂的用途
SG11202108566VA (en) 2019-02-06 2021-09-29 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CA3158195A1 (en) 2019-12-04 2021-06-10 Per-Goran Gillberg Benzothia(di)azepine compounds and their use as bile acid modulators
CA3158181A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
JP7665621B2 (ja) 2019-12-04 2025-04-21 アルビレオ・アクチボラグ ベンゾチアゼピン化合物及び胆汁酸モジュレータとしてのそれらの使用
WO2021110885A1 (en) 2019-12-04 2021-06-10 Albireo Ab Benzothiadiazepine compounds and their use as bile acid modulators
CN114786772B (zh) 2019-12-04 2024-04-09 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途
ES3002777T3 (en) 2020-08-03 2025-03-07 Albireo Ab Benzothia(di)azepine compounds and their use as bile acid modulators
AU2021379076A1 (en) 2020-11-12 2023-06-08 Albireo Ab Odevixibat for treating progressive familial intrahepatic cholestasis (pfic)
BR112023010799A2 (pt) 2020-12-04 2023-10-03 Albireo Ab Compostos de benzotia(di)azepina e seus usos como moduladores de ácidos biliares
CN117412955A (zh) 2021-06-03 2024-01-16 阿尔比里奥公司 苯并硫杂(二)氮杂环庚三烯化合物及其作为胆汁酸调节剂的用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084531A1 (ja) * 2007-12-27 2009-07-09 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体のモノセバシン酸塩
WO2009128421A1 (ja) * 2008-04-16 2009-10-22 キッセイ薬品工業株式会社 ピラゾール誘導体の1/2フマル酸塩

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004137245A (ja) 2002-08-23 2004-05-13 Kissei Pharmaceut Co Ltd ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体
AU2007243466B2 (en) * 2006-04-26 2012-01-19 F. Hoffmann-La Roche Ag Phosphoinositide 3-kinase inhibitor compounds and pharmaceutical compositions containing them
TW201105336A (en) * 2009-07-01 2011-02-16 Kissei Pharmaceutical Combined medicine of pyrazole derivative and biguanide drug
AR087701A1 (es) 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
US9273085B2 (en) * 2012-05-07 2016-03-01 Kissei Pharmaceutical Co., Ltd. Pyrazole derivative and use thereof for medical purposes

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009084531A1 (ja) * 2007-12-27 2009-07-09 Kissei Pharmaceutical Co., Ltd. ピラゾール誘導体のモノセバシン酸塩
WO2009128421A1 (ja) * 2008-04-16 2009-10-22 キッセイ薬品工業株式会社 ピラゾール誘導体の1/2フマル酸塩

Also Published As

Publication number Publication date
CN104284665B (zh) 2016-11-16
KR101868991B1 (ko) 2018-06-19
HK1204773A1 (en) 2015-12-04
EP2848254A1 (en) 2015-03-18
US9273085B2 (en) 2016-03-01
CA2872002C (en) 2019-01-15
JP2015083580A (ja) 2015-04-30
BR112014027841B1 (pt) 2022-08-09
MX359988B (es) 2018-10-18
JP5663699B2 (ja) 2015-02-04
US20160129031A1 (en) 2016-05-12
BR112014027841A8 (pt) 2021-09-28
PT2848254T (pt) 2016-10-05
KR20150013671A (ko) 2015-02-05
JPWO2013168671A1 (ja) 2016-01-07
EP2848254B1 (en) 2016-08-03
MX2014013696A (es) 2015-02-05
CN104284665A (zh) 2015-01-14
JP6105546B2 (ja) 2017-03-29
EP2848254A4 (en) 2015-07-15
CA2872002A1 (en) 2013-11-14
US20150141631A1 (en) 2015-05-21
RU2602739C2 (ru) 2016-11-20
DK2848254T3 (en) 2016-10-31
ES2601127T3 (es) 2017-02-14
US9694027B2 (en) 2017-07-04
RU2014149181A (ru) 2016-06-27
PL2848254T3 (pl) 2017-03-31
AU2013258566A1 (en) 2014-11-27
BR112014027841A2 (pt) 2017-06-27
WO2013168671A1 (ja) 2013-11-14

Similar Documents

Publication Publication Date Title
CA2872002C (en) Pyrazole derivative and use thereof for medical purposes
JP7312169B2 (ja) 遺伝性てんかん性障害の処置に使用するガナキソロン
CN103338768B (zh) 胃和结肠的配制剂及其制备和使用方法
CN114929209A (zh) 肌萎缩侧索硬化的治疗
JP6473254B2 (ja) 下痢を治療するための製品及び方法
JP7754799B2 (ja) てんかん重積状態の治療に使用するためのガナキソロン
US11834445B2 (en) Polymorphic forms of metopimazine
CN106456620A (zh) 胃轻瘫用5‑ht4受体激动剂
KR102078433B1 (ko) 변비증의 예방 또는 치료약
US20200038414A1 (en) Methods of treating constipation using aminosterol compositions
HK1204773B (en) Pyrazole derivative and use thereof for medical purposes
US20200038413A1 (en) Methods of treating parkinson's disease using aminosterol compositions
JP2026500731A (ja) 医薬組合せおよび医薬組成物、ならびにその使用方法
CN121534059A (zh) 一种治疗帕金森综合征或帕金森病的方法和药物组合物
US20110269792A1 (en) Compositions useful for treating irritable bowel syndrome

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)